Interventions that target drivers of noninitiation, particularly among racially and ethnically minoritized groups and older patients, may help ensure pharmacoequity for individuals diagnosed with ERBB2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.